E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

NCT01271504 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib
DRUG: Sorafenib

Sponsor

Eisai Inc.

Collaborators

[object Object]